Optimal dosing and monitoring guidance1
Dosing guidelines
Clinically driven monitoring
Before initiating treatment
- Conduct baseline liver tests (ALT, AST, and total bilirubin)
- Obtain a baseline ECG
- Correct hypokalemia and hypomagnesemia
Continued monitoring
- Conduct an ECG before each dose increase. After a stable dosage is established, monitor routinely for an effect on the QT interval
- Monitor 24-hour UFC, morning serum or plasma cortisol, and patient’s signs and symptoms for hypocortisolism periodically during Recorlev® treatment
Liver tests
- Serious hepatotoxicity has been reported in patients receiving Recorlev, and therefore frequent monitoring of liver tests is recommended
- Monitor liver enzymes and bilirubin weekly for at least 6 weeks after starting Recorlev, every 2 weeks for the next 6 weeks, monthly for the next 3 months, and then as clinically indicated
- After any dose interruption or dose increase, monitor on a weekly basis until a stable dosage is achieved
See Full Prescribing Information for dosage management and modification across AST/ALT and total bilirubin values.
A clinical pharmacist is available to support you in the management of monitoring and dose modifications.
Call 1-844-444-RCLV (7258) for support
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BID=twice daily; ECG=electrocardiogram; UFC=urinary free cortisol.
Reference: 1. Recorlev [prescribing information]. Chicago, IL; Xeris Pharmaceuticals, Inc.